Form 4: Iovance Biotherapeutics Executive Friedrich Graf Finckenstein Reports Stock Transactions
SEC Form 4 Filing
Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.
Summary
- On April 15, 2024, Friedrich Graf Finckenstein, the Chief Medical Officer of Iovance Biotherapeutics, had 2,812 restricted stock units (RSUs) vest.
- The company withheld 1,427 shares to cover mandatory tax obligations at a price of $11.89 per share.
- Following these transactions, Graf Finckenstein directly owns 42,562 shares of Iovance Biotherapeutics common stock and 8,439 RSUs.
- These remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This Form 4 filing is a neutral event, reflecting standard compensation practices and tax obligations. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Future Outlook
The remaining RSUs held by Friedrich Graf Finckenstein will continue to vest in equal quarterly installments.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.
Key Dates
| Date | Description |
|---|---|
| 01/14/2022 | Date of grant for the reported RSUs |
| 04/15/2024 | Date of RSU vesting and tax withholding. |
| 04/17/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.